Baer Investment Advisory LLC Has $576,000 Stock Position in Thermo Fisher Scientific Inc. $TMO

Baer Investment Advisory LLC lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 62.1% during the first quarter, HoldingsChannel reports. The firm owned 1,171 shares of the medical research company’s stock after selling 1,921 shares during the quarter. Baer Investment Advisory LLC’s holdings in Thermo Fisher Scientific were worth $576,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Turtle Creek Wealth Advisors LLC raised its holdings in shares of Thermo Fisher Scientific by 36.6% during the 1st quarter. Turtle Creek Wealth Advisors LLC now owns 2,680 shares of the medical research company’s stock worth $1,317,000 after buying an additional 718 shares in the last quarter. DB Fitzpatrick & Co Inc grew its position in Thermo Fisher Scientific by 2.4% in the first quarter. DB Fitzpatrick & Co Inc now owns 3,864 shares of the medical research company’s stock valued at $1,899,000 after acquiring an additional 92 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in Thermo Fisher Scientific during the first quarter worth about $8,231,000. Leonteq Securities AG lifted its holdings in shares of Thermo Fisher Scientific by 107.5% in the first quarter. Leonteq Securities AG now owns 4,059 shares of the medical research company’s stock worth $1,995,000 after acquiring an additional 2,103 shares during the last quarter. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its stake in shares of Thermo Fisher Scientific by 59.2% in the 1st quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 91,418 shares of the medical research company’s stock valued at $44,935,000 after purchasing an additional 33,985 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This trade represents a 1.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $522.38 on Friday. The firm’s fifty day simple moving average is $473.17 and its two-hundred day simple moving average is $518.15. Thermo Fisher Scientific Inc. has a 12 month low of $403.36 and a 12 month high of $643.99. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. The stock has a market capitalization of $194.13 billion, a P/E ratio of 28.72, a price-to-earnings-growth ratio of 2.32 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The company had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. During the same period in the previous year, the business earned $5.15 EPS. The firm’s revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 24.84 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.34%.

Analyst Ratings Changes

Several brokerages recently commented on TMO. Wolfe Research started coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price objective for the company. Royal Bank Of Canada set a $490.00 price target on Thermo Fisher Scientific and gave the company a “sector perform” rating in a research note on Thursday, May 14th. Wall Street Zen downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Morgan Stanley restated an “overweight” rating and set a $620.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. Finally, Sanford C. Bernstein began coverage on Thermo Fisher Scientific in a research report on Friday, June 26th. They issued a “market perform” rating and a $520.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $605.09.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.